Repligen (NASDAQ:RGEN) Sets New 52-Week High – Here’s Why

Repligen Corporation (NASDAQ:RGEN)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares changing hands. The stock had previously closed at $186.75.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on RGEN shares. HSBC cut their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $168.57.

Repligen Stock Down 2.4%

The company has a market cap of $10.29 billion, a PE ratio of 249.58, a price-to-earnings-growth ratio of 3.30 and a beta of 1.05. The business has a fifty day simple moving average of $163.00 and a two-hundred day simple moving average of $137.65. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the prior year, the firm earned $0.26 EPS. Repligen’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Transactions at Repligen

In related news, CFO Jason Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

Hedge funds have recently added to or reduced their stakes in the business. Tidal Investments LLC grew its position in shares of Repligen by 75.2% in the second quarter. Tidal Investments LLC now owns 8,863 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 3,803 shares during the period. Engineers Gate Manager LP grew its stake in Repligen by 146.0% during the second quarter. Engineers Gate Manager LP now owns 7,646 shares of the biotechnology company’s stock worth $1,043,000 after buying an additional 4,538 shares during the period. Waverly Advisors LLC boosted its position in Repligen by 10.1% during the 2nd quarter. Waverly Advisors LLC now owns 32,751 shares of the biotechnology company’s stock worth $4,469,000 after purchasing an additional 3,009 shares during the period. Nykredit A S acquired a new stake in shares of Repligen in the second quarter valued at about $269,000. Finally, Corient Private Wealth LP grew its position in Repligen by 420.9% in the second quarter. Corient Private Wealth LP now owns 11,319 shares of the biotechnology company’s stock valued at $1,544,000 after acquiring an additional 9,146 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.